Stock Market Reviews

XNCR (Xencor, Inc.) News

Get the latest news, insights, and market updates on XNCR (Xencor, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
  PASADENA, Calif., October 24, 2025--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC). The results were presented in a poster at the AACR-NCI-EORTC Conference on Molecular Targets and C
  Oct 24, 2025 - $XNCR
• Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
  PASADENA, Calif., October 21, 2025--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma.
  Oct 21, 2025 - $XNCR
• Xencor Stock Earns Relative Strength Rating Upgrade
  A Relative Strength Rating upgrade for Xencor shows improving technical performance. Will it continue?
  Oct 16, 2025 - $XNCR
• Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  PASADENA, Calif., October 14, 2025--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the upcoming presentation of initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a bispecific ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with clear cell renal cell carcinoma (ccRCC) in a poster at the AACR-NCI-EORTC Conference on Molecular Targets an
  Oct 14, 2025 - $XNCR
• Tracking the Evolving Narrative for Xencor After Mixed Analyst Developments
  Analysts have recently nudged their consensus price target for Xencor higher, moving it from $24.10 to $25.55 per share. While this adjustment reflects a cautious optimism around the company's evolving strategy, it comes amid a backdrop of mixed sentiment, balancing long-term promise in immunology and oncology with near-term uncertainties. Stay tuned to learn how you can monitor these narrative shifts and stay informed about key updates impacting Xencor's outlook. What Wall Street Has Been...
  Oct 9, 2025 - $XNCR
• Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
  Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  Sep 18, 2025 - $XNCR
• RBC Cuts Xencor (XNCR) Price Target but Keeps Outperform Rating
  Xencor, Inc. (NASDAQ:XNCR) is one of the Top 10 Stocks Under $10 That Could Triple. On August 21, RBC Capital reduced its price target for Xencor, Inc. (NASDAQ:XNCR) from $32 to $15 and maintained an Outperform rating. Despite lowering the price target, the firm believes that the current share price does not reflect the full […]
  Sep 8, 2025 - $XNCR
• Sector Update: Health Care Stocks Decline Late Afternoon
  Health care stocks retreated late Wednesday afternoon, with the NYSE Health Care Index down 0.3% and
  Sep 3, 2025 - $XNCR
• Sector Update: Health Care Stocks Retreat Wednesday Afternoon
  Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index down 0.4% and the H
  Sep 3, 2025 - $XNCR
• Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
  NasdaqGM:XNCR 1 Year Share Price vs Fair Value Explore Xencor's Fair Values from the Community and select yours A week...
  Aug 9, 2025 - $XNCR